You are here: Home » News-CM » Companies » News
Business Standard

Shilpa Medicare update on USFDA inspection of Polepally formulations unit

Capital Market 

Shilpa announced that the US intimated the Company that based on its inspection from 11 November to 30 November 2017, the Unit of the Company located at S-20 TO S-24/A, Pharmaceutical Formulations SEZ TSIIC, Green Industrial Park, Polepally, Jadcherla, Mahabubnagar, Telangana, India, has been determined that the inspection classification of this facility is VAI.

The is a confirmation that earlier status of our formulation Unit is maintained.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Sat, March 17 2018. 11:56 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU